



Figure 1S. Disposition of A) transplanted and B) non-transplanted patients with each subsequent line of treatment. Patient cohorts are stratified by date of diagnosis (2010-2015 and 2016-2020). Attrition with each line of therapy is shown in red, and the percentage of attrition if the percent of patients treated within each line of therapy that either died or progressed without receiving subsequent treatment.

Supplemental Table 1: Multivariable Model showing factors associated with attrition at each line of therapy by time cohort

| LOT | Predictors | t1= 2010-201 5 (n=2961) | | t2=2016-2020 (n=2587) | |
|-----------------|---------------------------|-------------------------|--------------------------|---------------------------|--------------------------|
| | | ASCT | Non-ASCT | ASCT | Non-ASCT |
| | | OR(95% CI) p value | OR(95% CI) p value | OR(95% CI) p value | OR(95% CI) p value |
| 1 | Sex: Female | Ref | Ref | Ref | Ref |
| | Male | 1.48 (1.05-2.10) | 1.17 (0.87-1.59) | 1.06 (0.61-1.85) | 1.24 (0.90-1.72) |
| | Age*: < 65 | Ref | Ref | Ref | Ref |
| | 65-74 | 1.36 (0.95-1.96) | 10.72 (0.47-1.08) | 2.02 (1.17-3.49) | 1.45 (0.83-2.52) |
| | 75-84 | 0 (0-Inf) | 1.24 (0.81-1.89) | 0 (0-Inf) | 2.11 (1.22-3.65) |
| | >=85 | 0 (0-Inf) | 3.12 (1.75-5.58) | 0 (0-Inf) | 4.59 (2.47-8.52) |
| | Progression time (m): ≥24 | Ref | Ref | Ref | Ref |
| | 12-24 | 1.33 (0.88-2.02) | 0.47 (0.29-0.76) | 2.83 (1.27-3.49) | 0.68 (0.38-1.22) |
| | 6-12 | 2.17 (1.20-3.95) | 1.07 (0.66-1.73) | 5.52 (2.17-14.02) | 1.76 (1.08-2.88) |
| | < 6 | 0.39 (0.12-1.31) | 2.97 (1.91-4.62) | 5.00 (1.82-13.75) | 4.33 (2.79-6.73) |
| Response: < PR | Ref | Ref | Ref | Ref | |
| ≥PR | 0.42 (0.22-0.80) | 0.70 (0.47-1.04) | 1.46 (0.40-5.32) | 0.81 (0.52-1.26) | |
| | | 1.85 (0.86-3.99) | 0.88 (0.48-1.61) | 1.17 (0.11-12.84) | 1.40 (0.79-2.48) |
| 2 | Sex: Female | Ref | Ref | Ref | Ref |
| | Male | 1.48 (0.98-2.24) | 1.40 (1.10-1.94) | 1.28 (0.68-2.39) | 1.40 (0.91-2.14) |
| | Age*: < 65 | Ref | Ref | Ref | Ref |
| | 65-74 | 1.52 (0.98-2.35) | 1.05 (0.63-1.73) | 1.24 (0.65-2.36) | 1.00 (0.52-1.92) |
| | 75-84 | 0 (0-Inf) | 1.31 (0.78-2.19) | 0 (0-Inf) | 1.05 (0.55-2.01) |
| | >=85 | 0 (0-Inf) | 3.75 (1.74-8.11) | 0 (0-Inf) | 2.45 (1.07-5.62) |
| | Progression time (m): ≥24 | Ref | Ref | Ref | Ref |
| | 12-24 | 1.47 (0.75-2.89) | 0.92 (0.58-1.47) | 2.08 (0.56-7.78) | 1.96 (0.98-3.94) |
| | 6-12 | 2.13 (1.15-3.95) | 1.01 (0.62-1.67) | 1.59 (0.51-4.98) | 2.27 (1.11-4.66) |
| | < 6 m | 4.58 (2.79-7.51) | 1.61 (1.03-2.52) | 5.20 (2.44-11.07) | 4.29 (2.56-7.19) |
| Response: <PR | Ref | Ref | Ref | Ref | |
| ≥PR | 1.16 (0.71-1.92) | 0.76 (0.51-1.15) | 2.45 (1.01-5.96) | 0.64 (0.38-1.08) | |
| Unknown | 1.88 (0.97-3.61) | 1.18 (0.65-2.13) | 2.00 (0.65-6.13) | 0.94 (0.48-1.82) | |
| 3 | Sex: Female | Ref | Ref | Ref | Ref |
| | Male | 1.20 (0.80-1.80) | 0.99 (0.66-1.48) | 0.93 (0.42-2.05) | 1.66 (0.89-3.09) |
| | Age*: < 65 | Ref | Ref | Ref | Ref |
| | 65-74 | 2.26 (1.45-3.53) | 0.91 (0.51-1.63) | 1.01 (0.43-2.39) | 1.54 (0.57-4.19) |
| | 75-84 | 0 (0-Inf) | 1.23 (0.66-2.29) | 0 (0-Inf) | 0.94 (0.35-2.54) |
| | >=85 | 0 (0-Inf) | 4.07 (1.07-15.41) | 0 (0-Inf) | 1.69 (0.37-7.85) |
| | Progression time (m): ≥24 | Ref | Ref | Ref | Ref |
| | 12-24 | 0.88 (0.40-1.92) | 2.83 (1.41-5.68) | 3.95 (0.31-50.10) | 3.17 (1.04-9.711) |
| | 6-12 | 0.93 (0.49-1.79) | 2.22 (1.18-4.19) | 12.74 (3.00-54.19) | 2.32 (0.71-7.56) |
| | < 6 | 2.43 (1.42-4.15) | 3.21 (1.82-5.67) | 4.34 (1.27-14.86) | 5.55 (2.41-12.78) |
| ResponseL3: <PR | Ref | Ref | Ref | Ref | |
| ≥PR | 0.92 (0.57-1.48) | 0.56 (0.34-0.92) | 0.58 (0.21-1.59) | 0.53 (0.24-1.18) | |
| Unknown | 1.11 (0.58-2.12) | 1.67 (0.83-3.35) | 0.82 (0.17-4.03) | 0.91 (0.33-2.48) | |

Values bolded p<0.05
*age at therapy initiation